Generic Name and Formulations:
Trazodone HCl 150mg, 300mg; scored ext-rel tabs.
Indications for OLEPTRO:
Major depressive disorder.
May be swallowed whole or broken in half along the scored line; do not crush or chew. Take on empty stomach at bedtime. ≥18yrs: Initially 150mg once daily. May increase by 75mg/day at 3-day intervals; max 375mg/day.
<18yrs: not established.
During or within 14 days of MAOIs. Concomitant linezolid or IV methylene blue.
Monitor for clinical worsening, suicidality and unusual changes in behavior, esp. during initiation and dose changes. Acute post MI: not recommended. Monitor for serotonin syndrome or neuroleptic malignant syndrome-like symptoms; discontinue if occurs. Bipolar disorder. Mania/hypomania. Psychosis. Cardiovascular disease. Predisposition to QT prolongation. Hypokalemia. Hypomagnesemia. Renal or hepatic impairment. Volume depletion. Predisposition to priapism (eg, sickle cell anemia, multiple myeloma, leukemia, or anatomically deformed penis). Angle closure glaucoma. Abnormal bleeding. Write ℞ for smallest practical amount. Reevaluate periodically. Avoid abrupt cessation. Elderly. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Potentiates alcohol, barbiturates, other CNS depressants, digoxin, phenytoin, antihypertensives. Monitor for serotonin syndrome with SSRIs, SNRIs, triptans (esp. during initiation and dose increases), MAOIs, linezolid, IV methylene blue, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort. Potentiated by CYP3A4 inhibitors (eg, ritonavir, indinavir, ketoconazole, itraconazole). Increased risk of arrhythmias with concomitant potent CYP3A4 inhibitors or drugs that prolong the QT interval; consider lower trazodone dose. Antagonized by CYP3A4 inducers (eg, carbamazepine). Increased risk of bleeding with concomitant NSAIDs, aspirin, anticoagulants. Monitor PT/INR with warfarin. Increased risk of hyponatremia with diuretics.
Somnolence/sedation, dizziness, constipation, blurred vision, headache, anticholinergic effects, GI upset, fatigue, myalgia, hypotension, syncope, hyponatremia, sexual dysfunction, CNS disturbances, dyspnea, night sweats, QT prolongation, torsades de pointes (possible); rare: priapism (discontinue if occurs).
Psychiatry Advisor Articles
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV
- Maintenance rTMS for Treatment-Resistant Depression
- New Study Compares Opioid Dependence Relapse Treatments
- Increase Use of Nursing Home for Patients With Cognitive Impairment Category
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder